Astellas

Graphic image of an arrow nailing the bullseye of a target

AbCellera tops ‘most aggressive’ hopes, putting rivals on notice

AbCellera saw phase 2 results “beyond even the most aggressive upside scenario” that its CEO had considered, sending shares up 30% in pre-market trading.

Nick Paul Taylor Aug 10, 2026 8:24am

for sale close down for sale sign business

Sangamo enters bankruptcy, reveals asset sales with 2 pharmas

Jun 23, 2026 10:57am

Fierce Pharma

Inside Astellas CEO's plan to counter Xtandi's patent cliff

Jun 11, 2026 6:00pm

Astellas closes stem cell unit’s Seattle site, layoffs incoming

Apr 14, 2026 10:45am

Metallic arrow symbols which are illuminated by blue and magenta lights merge on blue and magenta b

Astellas says 'I do' to Vir's T-cell engager in $1.7B deal

Feb 23, 2026 5:00pm

Fierce Pharma

Astellas lifts forecast as Vyloy surge counters trial miss

Feb 5, 2026 11:00am